TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Emcure Pharmaceuticals Ltd.

EMCURE on NSE · 19 Nov 2026

NIFTY 500

2,344.70 ▲ +0.42 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance

Filings

40 filings of EMCURE since February 2025.

board outcome 10, acquisition 9, transcript 8, presentation 7, credit rating 3, results 2

FiledTypeSubject
06 Nov 2026transcript
Acquisition, Dividend / buy-back, Guidance, Results
Emcure Pharmaceuticals Limited has informed the Exchange about Transcript
AI summary

Emcure filed the transcript of its Q2 FY27 earnings call held on November 3, 2026.

Management reported Q2 revenue of INR2,820 crores (up 24% year-on-year), EBITDA of INR575 crores (up 31%, margin 20.4%) and profit after tax of INR325 crores (up 29%).

Management raised its FY27 revenue growth outlook to exceed 20%, from mid-teens earlier, and expects the EBITDA margin improvement at the upper end of the 75-100 basis point guidance range.

Management said net debt stood at INR1,317 crores at September end and it remains committed to becoming net cash by the end of FY28.

Management said the Zuventus and Emcutix amalgamation into Emcure, approved by the Board on October 12, 2026, is subject to approvals including NCLT.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Nov 2026presentation
Acquisition, Results
Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentation
AI summary

Emcure Pharmaceuticals filed its investor presentation on unaudited financial results for the quarter and half year ended September 30, 2026 (Q2FY27).

Q2FY27 revenue was INR 28,205 Mn, up 24.3% YoY; EBITDA was INR 5,748 Mn (20.4% margin, up 103 bps YoY); PAT was INR 3,251 Mn (11.5% margin, up 45 bps YoY), with PAT growth of 29.3% YoY.

Management said domestic revenue grew 12% YoY in Q2FY27, up from 10% in Q1FY27, led by women's health, cardio-metabolics and CNS.

Management said Zuventus and Emcutix are to be merged with the holding company as part of simplifying the group holding structure.

Net debt rose to INR 13,171 Mn at September 30, 2026, which management attributed to the Mantra earnout and Gennova consolidation payments.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Nov 2026board outcome
Results
Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
AI summary

Emcure Pharmaceuticals filed the outcome of its board meeting held on November 3, 2026, approving unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026.

The Limited Review Reports on the results were issued by statutory auditor B S R & Co. LLP, dated November 3, 2026, with an unmodified conclusion.

The auditor noted that 18 subsidiaries were unreviewed, with total revenues of INR 2,633 million for the quarter and INR 5,479 million for the half-year, which management considers not material.

A press release on the results was enclosed as Annexure B.

The board meeting ran from 12:48 p.m. to 1:30 p.m. (IST).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Oct 2026schemeEmcure Pharmaceuticals Limited has informed the Exchange that the Board of Directors at the meeting held on October 12, 2026 have approved the proposed Scheme of Amalgamation of Zuventus Healthcare Limited and Emcutix Biopharmaceuticals LimNSE copy
25 Sep 2026presentation
Results
Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentation
AI summary

Emcure Pharmaceuticals filed its September 2026 Investor Presentation under Regulation 30 of the SEBI LODR Regulations, also posted on the company website.

FY26 revenue from operations was above USD 1 billion, with INR 92,035 Mn revenue (up 16.6% YoY) and PAT of INR 9,413 Mn (PAT growth of 33.1%).

FY26 EBITDA was INR 17,886 Mn with a margin of 19.4%; PAT margin was 10.2%, up 230 bps.

RoCE for FY26 was 23.7%, up 430 bps versus FY24, per the presentation.

FY26 revenue split was 44% domestic and 56% international.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 Sep 2026credit rating
Rating
Emcure Pharmaceuticals Limited has informed the Exchange about Credit Rating
AI summary

Emcure Pharmaceuticals filed under Regulation 30 to intimate that CARE Ratings has reaffirmed its bank facility ratings (press release dated August 31, 2026, received September 1, 2026).

Long-term bank facilities of Rs. 785.00 crore (enhanced from Rs. 557.50 crore) reaffirmed at CARE AA; Stable.

Long-term/short-term bank facilities of Rs. 1,563.00 crore (enhanced from Rs. 1,348.00 crore) reaffirmed at CARE AA; Stable / CARE A1+.

Short-term bank facilities of Rs. 52.00 crore reaffirmed at CARE A1+.

CARE cites FY26 revenue of about Rs. 9,322 crore (up 18% YoY) and PBILDT margin of 20.0% (FY25: 18.7%), and notes the all-cash acquisition of the remaining 12.05% stake in Gennova Biopharmaceuticals for about Rs. 232 crore, completed in July 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Aug 2026transcript
Acquisition, Guidance, Management change, Results
Emcure Pharmaceuticals Limited has informed the Exchange about Transcript
AI summary

Emcure Pharmaceuticals filed the transcript of its Q1 FY27 earnings call held on August 6, 2026.

Management said revenue grew 22.8% year-on-year to INR 2,580 crore, EBITDA rose 25.8% to INR 508 crore with margin at 19.7%, and profit after tax grew 36.2% to INR 292 crore.

India revenue grew 10.2% to INR 1,095 crore; international revenue grew 34.2% to INR 1,485 crore.

Management said Gennova is now a 100% subsidiary after acquiring a 12.05% minority stake, and Samit Mehta took over as Chief Operating Officer.

Chairman Berjis Desai will retire from the Board at the conclusion of the AGM, and Satish Mehta will take on the role of Chairman after the AGM.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Aug 2026presentation
Management change, Results
Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentation
AI summary

Emcure Pharmaceuticals filed its investor presentation on unaudited financial results for the quarter ended June 30, 2026 (Q1 FY27).

Q1 FY27 revenue was INR 25,804 Mn, up 22.8% YoY; EBITDA was INR 5,080 Mn at a 19.7% margin (up 50 bps); PAT was INR 2,925 Mn at an 11.3% margin (up 110 bps).

International business was 58% of revenue and grew 34.2% YoY; domestic revenue grew 10.2% YoY.

Mr. Satish Mehta is to take over as Chairman in addition to his role as Managing Director & CEO, after the upcoming AGM.

Gennova Biopharmaceuticals is now a wholly-owned subsidiary, with Mr. Samit Mehta as its CEO; Mr. Samit Mehta was also appointed COO of Emcure Pharmaceuticals.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Aug 2026board outcome
Management change, Results
Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
AI summary

Emcure Pharmaceuticals filed the outcome of its board meeting held on August 06, 2026, including unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with limited review reports from BSR & Co. LLP and a press release on the results (figures are in the annexures, not in the pages provided).

Mr. Berjis Desai (DIN 00153675), Chairman and non-executive non-independent director, will not seek re-appointment at the ensuing AGM and will cease as Chairman and director at the AGM's conclusion.

Board approved appointment of Mr. Raghu Kumar (DIN 01983106) as Additional Director (non-executive, independent) from August 06, 2026, for a first term of three years, subject to member approval.

Board approved appointment of Mr. Satish Mehta (DIN 00118691), Managing Director and CEO, as Chairman effective from conclusion of the AGM.

Board approved appointment of Mr. Samit Mehta (DIN 00332562), Wholetime Director, as Chief Operating Officer with immediate effect, and re-constitution of the Audit, Nomination and Remuneration, and Stakeholders' Relationship Committees effective from the AGM.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Jul 2026acquisition
Acquisition
Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition
AI summary

Emcure Pharmaceuticals filed under Regulation 30 an intimation of acquisition of 663,865 equity shares, 12.05% of the paid-up capital of its subsidiary Gennova Biopharmaceuticals Limited, from individual shareholders via share transfer agreements executed on July 13, 2026.

Post-acquisition, Gennova becomes a wholly-owned subsidiary; Emcure currently holds 87.95%.

Aggregate consideration is Rs. 2,318.7 million, payable in cash in one or more tranches on closing, with completion expected on or before July 31, 2026.

Gennova reported FY 2025-26 turnover of Rs. 4,917.42 million and PAT of Rs. 54.25 million.

The transaction is stated to be a related party transaction to be undertaken at arm's length; no governmental or regulatory approvals are stated as required.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Jul 2026acquisition
Acquisition
Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition
AI summary

Emcure Pharmaceuticals intimated under Regulation 30 that its subsidiary Marcan Pharmaceuticals Inc. entered into share purchase agreements on July 02, 2026 (EDT) to acquire all Class E Special Shares of Mantra Pharma Inc., a step-down subsidiary, making Mantra a 100% subsidiary of Marcan.

Consideration is cash of CAD 50 million for 100% of the Class E Special Shares; completion is indicated for July 03, 2026.

Mantra Pharma Inc., incorporated under Quebec law, is engaged in marketing and distribution of prescription drugs and natural health products in Canada, with annual turnover of CAD 96.67 million for FY2026 (CAD 81.01 million for FY2025).

The transaction is a related party transaction between two wholly-owned subsidiaries, exempted under Regulation 23(5) of the LODR Regulations, and is to be undertaken at arm's length; no specific government approvals are required beyond compliance under Canadian law.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Jun 2026presentation
Capex, Guidance, Results
Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentation
AI summary

Emcure Pharmaceuticals filed its Investor Presentation – June 2026 under Regulation 30 of the SEBI Listing Regulations, also available on the company website.

FY26 revenue from operations was INR 9,204 Cr, up 16.6% YoY; EBITDA was INR 1,789 Cr at a 19.4% margin (up 80 bps); Adj. PAT was INR 1,008 Cr at a 10.9% margin (up 189 bps).

FY26 ROCE was 23.8%, up 180 bps; the company described FY26 revenue growth as above its guidance.

The presentation states TTM revenue from operations above USD 1 Bn, with about 44% TTM domestic contribution and about 50% of revenue from complex products.

Management highlighted operating leverage, with PCPM scaling about 30% from INR 5.4 lacs to INR 7.0 lacs, and a pipeline spanning biologics, NDDS, complex injectables and LAI.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 May 2026transcript
Acquisition, Dividend / buy-back, Guidance, Results
Emcure Pharmaceuticals Limited has informed the Exchange about Transcript
AI summary

Emcure Pharmaceuticals filed the transcript of its Q4 FY26 earnings call held on May 5, 2026.

Management said FY26 revenue crossed INR9,204 crores, up 16.6% year-on-year, and adjusted PAT grew more than 40%; FY26 domestic revenue grew 10% to INR4,027 crores and international revenue grew 22.2% to INR5,177 crores.

Q4 FY26 revenue rose 16.7% to INR2,470 crores, with domestic revenue up 5.2% to INR977 crores due to softness in Zuventus; adjusted PAT was INR279 crores, up 36%.

Management guided to low to mid-teen revenue growth in FY27 and EBITDA margin expansion of 75 to 100 basis points, assuming stable regulations and macroeconomic conditions.

Net debt as of March 31, 2026 was INR1,054 crores, which management attributed mainly to payouts for Manx and the Zuventus minority stake acquisition.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 May 2026presentation
Acquisition, Results
Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentation
AI summary

Emcure Pharmaceuticals filed a presentation on its audited consolidated and standalone financial results for the quarter and year ended March 31, 2026.

Q4 FY26 revenue was ₹2,470 Cr, up 16.7% YoY; EBITDA was ₹485 Cr at a 19.7% margin; adjusted PAT was ₹279 Cr at an 11.3% margin.

FY26 revenue was ₹9,204 Cr, up 16.6% YoY, which management said was above guidance; FY26 EBITDA was ₹1,789 Cr at a 19.4% margin; adjusted PAT was ₹1,008 Cr at a 10.9% margin.

Management said international markets were strong (Q4 international revenue up 25.7% YoY) while the domestic business was resilient (Q4 revenue up 5.2%), with domestic performance softer due to the Zuventus portfolio and team reorganization.

Management highlighted partnerships with Novo Nordisk (Poviztra), Sanofi (Amaryl and Cetapin) and Roche, the full consolidation of Zuventus through a minority stake buyout, and the Manx and Cutimed acquisitions.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
05 May 2026board outcome
Dividend / buy-back, Management change, Results
Outcome of the Board Meeting held on May 05, 2026.
AI summary

Emcure Pharmaceuticals filed the outcome of its board meeting held on May 05, 2026, approving audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with unmodified audit opinions from statutory auditors BSR & Co. LLP.

The board recommended a final dividend of Rs. 3.60 per equity share of Rs. 10 each (36%) for FY2026, subject to shareholder approval at the ensuing AGM.

The board approved re-appointment of Dr. Mukund Gurjar as Whole-time Director for one year from August 28, 2026, subject to shareholder approval.

The board approved re-appointment of Mr. Satish Mehta as Managing Director for five years from April 01, 2027, subject to shareholder approval.

A press release on the annual results is enclosed, but its text is not in the pages provided, so management's commentary on the business is not available.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 Apr 2026acquisition
Acquisition
Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition
AI summary

Emcure filed an intimation under Regulation 30 on April 1, 2026 that Mantra Pharma Inc., a step-down subsidiary, signed a share purchase agreement to acquire 100% of Cutimed Inc., a Canadian cosmetics and personal care company.

The aggregate consideration is up to CAD 5.05 million, paid in cash, and Cutimed reported annual turnover of CAD 2.8 million for FY2025.

Cutimed was then amalgamated with Mantra Pharma Inc. effective April 1, 2026 (EDT) under the short-form amalgamation procedure of the Québec Business Corporations Act.

The company stated that the acquisition is not a related party transaction and that no specific government approvals are required.

The company stated the transaction strengthens its portfolio in Canadian dermatological and cosmetic product segments and supports long-term growth strategy.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
09 Mar 2026board outcome
Legal, Management change
Emcure Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on March 09, 2026.
AI summary

Emcure Pharmaceuticals filed the outcome of its board meeting held on March 09, 2026 (meeting ran 12:15 p.m. to 12:40 p.m. IST).

The board approved the appointment of Mr. C S Muralidharan (DIN: 00014740) as Additional Director (Non-Executive and Independent) and as Independent Director for a first term of three consecutive years, both with effect from April 01, 2026, subject to member approval.

Mr. Muralidharan has about 40 years of corporate experience in hydrocarbon and pharmaceutical sectors and was previously Group Chief Financial Officer of Sun Pharmaceutical Industries Limited; he is not related to any director or key managerial personnel.

The board approved a postal ballot through remote e-voting to seek member approval for the independent director appointment; the notice will be issued in due course.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
20 Feb 2026presentation
Results
Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentation
AI summary

Emcure Pharmaceuticals filed an investor presentation for investor conferences on February 23 and 24, 2026, also available on its website.

Presentation shows TTM revenue from operations of INR 8,850 Cr, with 45% domestic contribution and 55% international.

Overall revenue grew 16.5% in 9M FY26 to INR 6,734 Cr versus INR 5,780 Cr in 9M FY25; FY25 overall revenue was INR 7,896 Cr versus INR 6,658 Cr in FY24.

EBITDA margin rose to 22.7% in 9M FY26 from 19.4% in FY24 and 22.0% in FY25; PAT margin rose to 10.4% from 7.9% in FY24; RoCE rose to 10.4% in 9M FY26 (per the margin/RoCE chart).

Management highlights include launch of Poviztra, a biological injectable semaglutide, and a pipeline spanning biologics, NDDS, complex injectables, ADCs and long-acting injectables.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
10 Feb 2026transcript
Acquisition, Guidance, Results
Emcure Pharmaceuticals Limited has informed the Exchange about Transcript
AI summary

Emcure filed the transcript of its Q3 FY26 earnings call held on February 4, 2026.

Management said revenue from operations grew 20.4% year-on-year to INR 2,363 crores, and profit after tax was INR 231 crores (48% growth), after a one-time exceptional expense of INR 38 crores related to Labour Code changes; adjusted PAT was INR 260 crores (65% growth).

Management said EBITDA margin was 19.5% (up from 18.4% in Q3 FY25), while gross margin fell to 59.3% from 60.1%, attributed to the Sanofi OAD in-licensing and business mix; management expects FY26 gross margin in the 60% range.

Management said Canada revenue growth is expected to be in the mid-teens for the year, and that it is too early to give specific guidance for FY27.

Net debt was INR 1,203 crores, which management said increased mainly due to the payout for the Zuventus minority stake.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Feb 2026board outcome
Legal, Management change, Results
Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
AI summary

Board meeting held on February 04, 2026 approved unaudited consolidated and standalone financial results for the quarter and nine months ended December 31, 2025, with limited review reports from BSR & Co. LLP.

Board approved appointment of Ms. Amruta Jana Yangalwar as Company Secretary and Compliance Officer.

Board approved re-appointment of Dr. Shailesh Kripalu Ayyangar (five years from June 02, 2026), Mr. Vijay Keshav Gokhale (five years from April 16, 2026) and Dr. Vidya Rajiv Yeravdekar (three years from April 16, 2026) as Independent Directors, subject to member approval.

Board approved a postal ballot through remote e-voting to seek member approval for the Independent Director re-appointments; notice to be issued later.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 Nov 2025presentation
Guidance, Results
Emcure Pharmaceuticals Limited has informed the Exchange about Investor Presentation
AI summary

Emcure Pharmaceuticals filed an investor presentation (November 2025) for investor conferences on November 19 and 20, 2025, under Regulation 30 of the SEBI LODR Regulations.

FY25 revenue from operations was INR 7,896 Cr, with 46.3% from India (FY24: INR 6,658 Cr overall); 1H FY26 revenue grew 15% to INR 4,370 Cr (1H FY25: INR 3,817 Cr).

PAT margin rose over 250bps in the last six quarters, with PAT growth of 30%+; RoCE was 22.0% in FY25 (FY24: 19.4%).

Management stated that revenue has grown mid-to-high teens over the last six quarters, faster than industry growth across markets.

The presentation lists a pipeline of products across biologics, novel drug delivery systems, complex injectables, antibody-drug conjugates and long-acting injectables.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
17 Nov 2025transcript
Acquisition, Dividend / buy-back, Guidance, Results
Emcure Pharmaceuticals Limited has informed the Exchange about Transcript
AI summary

Emcure filed the transcript of its Q2 FY26 earnings conference call held on November 11, 2025.

Management (Satish Mehta) said revenue grew 13% YoY and PAT rose 25% to INR 251 crores, the highest quarterly profit, and the company remains on track for its high-level guidance.

CFO Tajuddin Shaikh said revenue from operations grew 13.4% YoY to INR 2,270 crores, EBITDA excluding other income rose 15.2% to INR 439 crores (19.3% margin), and net debt was INR 837 crores, up due to the partial payout for the ZHL stake purchase.

Management said the Novo Nordisk partnership to build a second semaglutide brand, Poviztra, gives early entry into the obesity market, and that the company expects base margins to improve by about 150 basis points this year.

Management said it now expects to be debt-free in 18 to 24 months, after the Zuventus stake acquisition, versus its earlier FY26 target.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Nov 2025board outcome
Results
Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
AI summary

Emcure Pharmaceuticals filed the outcome of its board meeting held on November 11, 2025, which approved the unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2025.

The limited review reports by auditor BSR & Co. LLP are enclosed, with an unmodified conclusion; the auditor notes 18 unreviewed subsidiaries that it states are not material to the group.

A press release on the results is enclosed as Annexure B, but its contents are not included in the pages provided.

The board meeting ran from 12.28 p.m. to 1.23 p.m. (IST).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
17 Oct 2025credit rating
Rating
Emcure Pharmaceuticals Limited has informed the Exchange about Credit Rating- Revision
AI summary

Emcure Pharmaceuticals Limited filed an intimation under Regulation 30 of the SEBI LODR Regulations on a revision in credit rating dated October 17, 2025.

CRISIL Ratings Limited upgraded the long-term rating on bank loan facilities of Rs. 1957.5 crores to CRISIL AA-/Positive from CRISIL AA-/Stable.

CRISIL re-affirmed the short-term rating on the same bank loan facilities at CRISIL A1+.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
08 Oct 2025credit rating
Rating
Emcure Pharmaceuticals Limited has informed the Exchange about Credit Rating
AI summary

Emcure Pharmaceuticals filed an intimation under Regulation 30 of the SEBI LODR Regulations on credit ratings assigned by CARE Ratings, received October 08, 2025.

Long-term bank facilities of Rs. 557.50 crore upgraded to CARE AA; Stable from CARE AA-; Stable.

Long-term/short-term bank facilities of Rs. 175.00 crore assigned CARE AA; Stable / CARE A1+.

Long-term/short-term bank facilities of Rs. 1,173.00 crore (reduced from Rs. 1,286.00 crore) upgraded to CARE AA; Stable / CARE A1+ (long-term) with short-term rating reaffirmed.

Short-term bank facilities of Rs. 52.00 crore (reduced from Rs. 114.00 crore) reaffirmed at CARE A1+.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Oct 2025acquisition
Acquisition
Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition
AI summary

Emcure Pharmaceuticals informed the exchanges (Oct 3, 2025) that it has completed the acquisition of 4,095,180 equity shares (20.42%) of Zuventus Healthcare Limited from individual shareholders, for an aggregate consideration of Rs. 7,249 Millions.

With this acquisition, Zuventus becomes a wholly owned subsidiary of Emcure; Emcure already held 79.58% before the deal.

The shares have been credited to Emcure's demat account after completion of due procedures.

Per the June 21, 2025 intimation, Zuventus reported turnover of Rs. 10,798.99 Millions and PAT of Rs. 1,347.82 Millions for FY ended March 31, 2025.

The consideration was payable in cash; the acquisition was originally expected to complete on or before September 30, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Aug 2025transcript
Acquisition, Guidance, Management change, Results
Emcure Pharmaceuticals Limited has informed the Exchange about Transcript
AI summary

Emcure Pharmaceuticals filed the transcript of its Q1 FY26 earnings conference call, held on August 7, 2025.

Management said revenue from operations grew 15.7% year-on-year to INR 2,101 crores, EBITDA (excluding other income) grew 20.1% to INR 404 crores, and profit after tax rose 41% to INR 215 crores, the company's highest quarterly profit.

Management said the domestic business grew 9.4% to INR 995 crores and international business grew 22% to INR 1,106 crores, with emerging markets up 42% and Canada up 16.4%.

Management said it expanded its Sanofi partnership to market the oral diabetes brands Amaryl and Cetapin from August 1, 2025, with the portfolio expected to be about INR 200 crores annualised.

Management said US exposure is less than 3% of sales and that it is targeting 4% to 5% volume growth in India for the full year.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 Aug 2025board outcome
Results
Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AI summary

Board of Emcure Pharmaceuticals approved the unaudited consolidated and standalone financial results for the quarter ended June 30, 2025, at a meeting held August 07, 2025 (11.45 a.m. to 1.20 p.m. IST).

Limited review reports on the results were issued by statutory auditors B S R & Co. LLP, with an unmodified conclusion.

The consolidated statement covers the parent and 18 subsidiaries; 17 subsidiaries' unreviewed interim figures show total revenues of Rs. 1,833 million and net profit after tax of Rs. 108 million (before consolidation adjustments).

A press release on the quarterly results was enclosed as Annexure B; its figures are not included in the pages provided.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Jul 2025acquisition
Acquisition
Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition
AI summary

Emcure Pharmaceuticals filed on July 4, 2025 to confirm incorporation of a wholly-owned subsidiary, Emcure Wellness Private Limited, in Pune, Maharashtra.

The Registrar of Companies approved and incorporated the subsidiary on July 3, 2025; the particulars in the June 21, 2025 disclosure remain unchanged.

The June 21, 2025 board approval set proposed authorised share capital of Rs. 10,00,00,000 and paid-up share capital of Rs. 1,00,000, fully subscribed in cash at face value of Rs. 10 per share.

The subsidiary is to manufacture, promote, sell and distribute pharmaceuticals and related products.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
21 Jun 2025acquisition
Acquisition
Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition
AI summary

Emcure Pharmaceuticals filed a Regulation 30 intimation dated June 21, 2025, about its board approving, at a meeting held the same day, the incorporation of a wholly-owned subsidiary.

The proposed subsidiary is "Emcure Wellness Private Limited" (or another name approved by the Ministry of Corporate Affairs), to be incorporated in Pune, Maharashtra, India.

Proposed authorised share capital is Rs. 10,00,00,000 (Rupees Ten Crores); proposed paid-up share capital is Rs. 1,00,000 (Rupees One Lakh), subscribed 100% in cash at face value of Rs. 10 per share.

The subsidiary will manufacture, promote, sell and distribute pharmaceuticals and related products; it is yet to be incorporated, so turnover is not applicable.

No governmental or regulatory approvals are stated as required, and no completion period is indicated.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
21 Jun 2025acquisition
Acquisition
Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition
AI summary

Board of Emcure Pharmaceuticals approved on June 21, 2025 the acquisition of 4,095,180 equity shares (20.42%) of subsidiary Zuventus Healthcare Limited from its individual shareholders, making Zuventus a wholly-owned subsidiary.

Company's existing stake in Zuventus is 79.58%; post-acquisition it will be 100%.

Aggregate consideration is Rs. 7,249 Millions, payable in cash in one or more tranches on closing, based on valuation.

Zuventus reported turnover of Rs. 10,798.99 Millions and PAT of Rs. 1,347.82 Millions for FY ended March 31, 2025.

Completion is indicated on or before September 30, 2025; no governmental or regulatory approvals are required.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
21 Jun 2025board outcome
Acquisition, Capex, Legal
Emcure Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on Jun 21, 2025.
AI summary

Emcure Pharmaceuticals filed the outcome of its board meeting held on June 21, 2025.

The board approved acquisition of 4,095,180 equity shares (20.42%) of subsidiary Zuventus Healthcare Limited from its individual shareholders, making Zuventus a wholly-owned subsidiary; the company already holds 79.58%.

Zuventus reported turnover of Rs. 10,798.99 Millions and PAT of Rs. 1,347.82 Millions for FY ended March 31, 2025.

The board approved requests from certain promoter and promoter group members to re-classify to the 'Public' category, subject to no-objection certificates from BSE and NSE and shareholder approval.

The board approved incorporation of a wholly-owned subsidiary, Emcure Wellness Private Limited, in Pune, Maharashtra.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
17 Jun 2025acquisition
Capex, Legal
Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition
AI summary

Emcure Pharmaceuticals filed a Regulation 30 disclosure dated June 17, 2025 updating its May 22, 2025 intimation on a wholly-owned subsidiary.

The company applied to the ROC, Pune, for the name "Emcure Lifesciences Private Limited" instead of "Emcure Generics Private Limited", and the name was approved.

The ROC approved incorporation of "Emcure Lifesciences Private Limited" as a wholly-owned subsidiary on June 17, 2025; all other particulars match the May 22, 2025 disclosure.

Per the May 22 disclosure, proposed authorized share capital is Rs. 10,00,00,000 and paid-up share capital is Rs. 1,00,000, fully subscribed by the company in cash at Rs. 10 per share; the subsidiary will manufacture, promote, sell and distribute pharmaceuticals.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
02 Jun 2025acquisition
Acquisition, Capex
Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition
AI summary

Emcure Pharmaceuticals entered into a Share Subscription and Shareholders' Agreement and two Power Transfer Agreements dated June 02, 2025 to acquire at least 26% (fully diluted) of Torrent Urja 37 Private Limited.

Target is a wholly owned subsidiary of Torrent Green Energy Private Limited, incorporated January 20, 2025, with paid-up share capital of Rs. 5,00,000; its first AGM is pending so turnover and PAT are unavailable.

Target is setting up a 11.27 MWp ground-mounted solar power facility in Gujarat, to be a captive power project; Emcure will buy the electricity generated to meet energy needs at identified facilities in Gujarat.

Consideration is cash of Rs. 3,71,87,740; completion is subject to consents including open access approval for captive consumption of electricity.

The transaction is stated not to be a related party transaction and promoter/promoter group has no interest in the target.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
28 May 2025transcript
Dividend / buy-back, Guidance, Results
Emcure Pharmaceuticals Limited has informed the Exchange about Transcript
AI summary

Emcure filed the transcript of its Q4 FY25 earnings call held on May 22, 2025.

Management said Q4 FY25 revenue from operations grew 19.5% year-over-year to INR 2,116 crores, and FY25 revenue grew 19% to INR 7,896 crores; FY25 PAT was INR 707 crores, up 34.1%.

Management guided to FY26 top-line growth of 13% to 14% with around 150 bps margin improvement over the year.

The Board recommended a dividend of INR 3 per share; net debt was INR 488 crores at year end versus INR 1,558 crores in FY24.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
22 May 2025board outcome
Capex, Dividend / buy-back, Management change, Results
Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
AI summary

Board of Emcure Pharmaceuticals approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025, with unmodified audit opinions from statutory auditors BSR & Co. LLP.

Board recommended a final dividend of Rs. 3 per equity share (30% on Rs. 10 face value) for FY2025, subject to shareholder approval at the AGM.

Board approved re-appointment of Dr. Mukund Gurjar as Whole-time Director for one year from August 28, 2025, subject to shareholder approval at the AGM.

Board approved appointment of M/s. SVD & Associates as Secretarial Auditors for five consecutive years from FY2025-26, subject to shareholder approval at the AGM.

Board approved incorporation of a wholly-owned subsidiary, Emcure Generics Private Limited, in Pune, Maharashtra.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Feb 2025transcript
Capex, Guidance, Results
Emcure Pharmaceuticals Limited has informed the Exchange about Transcript
AI summary

Emcure Pharmaceuticals filed the transcript of its Q3 FY25 earnings conference call held on February 6, 2025.

Management said Q3 revenue from operations grew 18% year-on-year to INR 1,963 crores and adjusted PAT grew 36% year-on-year; reported PAT was INR 156 crores.

CFO Tajuddin Shaikh said domestic business grew 12% to INR 888 crores, international markets grew 23% to INR 1,075 crores, and gross margin was 60.1% against 62.7% a year earlier, attributed to business mix from the lower-margin Sanofi business.

EBITDA without other income grew 23% to INR 362 crores, with EBITDA margin at 18.4%; net debt was INR 600 crores against INR 705 crores in Q2.

Management said it targets a 300-400 basis point margin improvement over the coming years and that Emcutix (Derma) will launch products from FY26; Samit Mehta said Emcure expects to be in the first wave of semaglutide entrants in India after loss of exclusivity in March 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Feb 2025results
Results
Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024
AI summary

Emcure Pharmaceuticals filed its integrated filing (financial) for the quarter and nine months ended December 31, 2024, enclosing the financial results already filed with the exchanges on February 06, 2025.

The filing states that the related party transactions disclosure is not applicable for the quarter, as it is submitted half-yearly, and that there is no default on loans or debt securities.

BS R & Co. LLP issued a limited review report on the unaudited consolidated results, with no modification to its conclusion.

The review report notes that 17 subsidiaries were not reviewed; their total revenues were Rs. 2,230.03 million for the quarter and Rs. 6,309.33 million for the nine months, and the auditor considers these not material to the Group.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Feb 2025results
Results
Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
AI summary

Emcure Pharmaceuticals filed the outcome of its board meeting held on February 6, 2025, which approved the unaudited consolidated and standalone financial results for the quarter and nine months ended December 31, 2024.

The limited review reports by BSR & Co. LLP are enclosed, with a conclusion that nothing came to their attention requiring modification.

The limited review notes that the statement includes 17 unreviewed subsidiaries, with total revenues of Rs. 2,230.03 million for the quarter and Rs. 6,309.33 million for the nine months, which the management considers not material to the group.

A press release on the key updates for the period is enclosed as Annexure B, but its content is not included in the pages provided.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Feb 2025board outcome
Results
Emcure Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on February 06, 2025.
AI summary

Emcure Pharmaceuticals filed the outcome of its board meeting held on February 6, 2025, which approved the unaudited consolidated and standalone financial results for the quarter and nine months ended December 31, 2024.

The limited review reports from auditor BSR & Co. LLP are enclosed, with the auditor's conclusion not modified on the subsidiaries not reviewed (17 subsidiaries, total revenue of Rs. 2,230.03 million for the quarter and Rs. 6,309.33 million for nine months, stated as not material to the group).

A press release on the results is enclosed as Annexure B; the board meeting ran from 2:00 p.m. to 2:45 p.m. IST.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy

The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in